Kolexia
Negrier Marie-Sylvie Oncologie médicale
Negrier Marie-Sylvie
Oncologie médicale
Centre Léon-Bérard
Lyon, France
210 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Néphrocarcinome Carcinomes Tumeurs du rein Métastase tumorale Mélanome Tumeurs du cerveau Hypertension artérielle Récidive tumorale locale Néovascularisation pathologique

Collaborateurs

Voir plus
Escudier Bernard
Escudier Bernard
Gustave-Roussy, Villejuif, France
Albiges Laurence
Albiges Laurence
Gustave-Roussy, Villejuif, France
Barthelemy Philippe
Barthelemy Philippe
Hôpital Civil, Strasbourg, France
Gross-Goupil Marine
Gross-Goupil Marine
Hôpital Saint-André, Bordeaux, France

Industries

Voir plus
Ipsen
25 collaboration(s)
Dernière en 2023
Pfizer
23 collaboration(s)
Dernière en 2023
BMS
18 collaboration(s)
Dernière en 2023
MSD
18 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
PROFILER: Program to Establish the Genetic and Immunologic Profile of Patient's Tumor for All Types of Advanced Cancer
Essai Clinique (Centre Léon-Bérard)   01 mars 2024
MOST plus: A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally-advanced or Metastatic Solid Tumors
Essai Clinique (Centre Léon-Bérard)   09 février 2024
Safety and efficacy of nivolumab in elderly patients with metastatic clear cell renal cell carcinoma: Analysis of the NIVOREN GETUG-AFU 26 study.
European journal of cancer (Oxford, England : 1990)   03 février 2024
PAXIPEM: Multicenter Phase II Study of Axitinib +/- Pembrolizumab in First Line Treatment for Patients With Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (PRCC)
Essai Clinique (Centre Léon-Bérard)   24 janvier 2024
Cancer du rein métastatique
Edimark   24 janvier 2024
A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101): A PHASE 3, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH AXITINIB (INLYTA(REGISTERED)) VERSUS SUNITINIB (SUTENT(REGISTERED)) MONOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA
Essai Clinique (Pfizer)   21 décembre 2023
Real-World Treatment Patterns and Effectiveness of Patients With Advanced Renal Cell Carcinoma: A Nationwide Observational Study.
Clinical genitourinary cancer   24 novembre 2023
Comprehensive analyses of immune tumor microenvironment in papillary renal cell carcinoma.
Journal for immunotherapy of cancer   09 novembre 2023
Adrenal Metastases Are Associated with Poor Outcomes in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Nivolumab in the GETUG-AFU-26 NIVOREN Phase 2 Trial.
European urology oncology   07 octobre 2023
1883MO MEDI5752 (volrustomig), a novel PD-1/CTLA-4 bispecific antibody, in the first-line (1L) treatment of 65 patients (pts) with advanced clear cell renal cell carcinoma (aRCC)
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023